Condition: Foregut Adenocarcinoma · Esophageal Adenocarcinoma · Gastroesophageal Adenocarcinoma · Sponsor: Yale University
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.
This description comes directly from the study's public registry record.
Wumi Jemiseye, MPH · 203-737-4475 · wumi.jemiseye@yale.edu
Always discuss trial participation with your own doctor first.
| Smilow Cancer Center | New Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07282912